Sveriges mest populära poddar
Pharmaceutical Executive
VetenskapLife Science

Pharmaceutical Executive Daily: FDA Approves Utebzi and Capvaxive

4 min•18 juni 2026
In today's Pharmaceutical Executive Daily, Biogen announces its second acquisition of 2026, a deal worth up to $1 billion for private immunology biotech RayThera, FDA approves Utebzi as the first and only oral carbapenem antibiotic for adults with complicated urinary tract infections, and FDA expands the indication for Merck's Capvaxive to include children and adolescents aged 2 through 17 with chronic medical conditions at increased risk for pneumococcal disease.

Fler avsnitt av Pharmaceutical Executive

Visa alla avsnitt av Pharmaceutical Executive
Pharmaceutical Executive Daily: The Changing Reality of Pharmaceutical Commercialization
•3 min
Pharmaceutical Executive Daily: The Medicare GLP-1 Bridge
•3 min
Pharmaceutical Executive Daily: FDA Names Seven Participants to Precheck Program
•3 min
Pharmaceutical Executive Daily: Ipsen Enters Merger Agreement to Acquire Kartos Therapeutics
•4 min
Pharmaceutical Executive Daily: FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer
•3 min
Pharmaceutical Executive Daily: Eli Lilly and Abbisko Announce Drug Development Collaboration
•3 min
Pharmaceutical Executive Daily: FDA Pilot Targets Faster Early-Stage Drug Trial Starts
•4 min
Pharmaceutical Executive Daily: AbbVie Acquires Apogee Therapeutics for $10.9 Billion
•3 min
Pharmaceutical Executive Daily: FDA Advisory Committee Votes Unanimously in Favor of The Benefit-Risk Profile of Moderna's mRNA-1010
•4 min
Pharmaceutical Executive Daily: Meaningfully Improving Therapy Persistence in Patient Support Programs
•4 min

Pharmaceutical Executive med Pharmaceutical Executive Podcast finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.